THE ROLE OF BIOTECHNOLOGY IN DEVELOPING TARGETED DRUG DELIVERY SYSTEMS FOR CANCER THERAPY

Abstract

Cancer remains one of the larger health issues within the world and it claims the lives of many people since conventional chemotherapy is not extremely effective, and it could even be harmful to the entire body.  With the use of biotechnology it has now become practical to develop a targeted drug delivery system (TDDS) whereby drugs are only released to those parts of the body where it is needed more and this makes the drug more effective and has less side effects.The paper examines how biotechnology has enhanced nanoparticle engineering, ligand mediated targeting and gene based vectors to TDDS.  This was done through a comprehensive comparison of nanoparticle platforms, tumor-specific ligands, pharmacokinetic properties and gene therapy vectors. This was followed by the representation aspects of the visual and tabular modeling to evaluate the effectiveness, safety and individualization of the therapies.The findings showed that nanoparticle based systems such as liposomes, dendrimers, and antibody drug conjugates performed much better in entrapment of drugs, enhancing their half-life, and delivery of them at the correct place compared to conventional methods.  TDDS produced using individualized genetic mutations of every patient was more deliverable and less toxic.  The use of stimuli-responsive delivery devices which react to pH, temperature as well as enzymes also proved effective in enhancing the mechanism of drug delivery within the tumor.  The adverse effects were lesser and that it worked well especially in people with other types of cancer.In conclusion, the idea to combine biotechnology with targeted delivery is a revolutionary cancer treatment mechanism.  Based on the research it can be seen that there is plenty of therapeutic potential of TDDS to make things more accurate, less risky and more individualized.  However, they still have issues to address, such as tumor heterogeneity, off-target biodistribution, and possibilities of scale up production.  The only way to standardize these results into patient centered cancer therapies will be to continue to generate new ideas and collaborate trans-disciplinary..